Advertisement
Organisation › Details
HalioDx SAS
HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis, enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications. HalioDx has an experienced team of more than 135 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI). *
Start | 2015-03-23 established (s-off) | |
Predecessor | Qiagen Marseille S.A. | |
Industry | molecular diagnostics | |
Industry 2 | Immunoscore® cancer prognosis tool | |
Person | Fert, Vincent (HalioDx 201503– CEO + CO-founder before Ipsogen 200708– President + CEO) | |
Person 2 | Galon, Jérôme (INSERM 201507 + Co-Founder of HalioDx) | |
Region | Marseille | |
Country | France | |
Street | 163 avenue de Luminy Luminy Biotech Entreprises, Case 923 | |
City | 13288 Marseille Cedex 09 | |
Tel | +33-4-9129-3090 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2019-04-19) |
* Document for »About Section«: HalioDx SAS. (4/19/19). "Press Release: HalioDx Signs an Exclusive Agreement with Genecast to Make Immunoscore Available in China". Marseille. | ||
Record changed: 2024-03-30 |
Advertisement
More documents for Veracyte (Group)
- [1] Veracyte, Inc.. (6/1/21). "Press Release: Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth". South San Francisco, CA....
- [2] Stilla Technologies SAS. (2/2/21). "Press Release: Stilla Expands Leadership Team to Drive Next Phase of Global Commercial Growth; Appoints Philippe Mourere as President and CEO and Founder Rémi Dangla as CTO". Boston, MA & Paris....
- [3] Veracyte, Inc.. (12/22/20). "Press Release: Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer". Whippany, NJ & San Francisco, CA....
- [4] Bruker Corporation. (9/8/20). "Press Release: Bruker Appoints Bonnie H. Anderson to its Board of Directors". Billerica, MA....
- [5] HalioDx SAS. (4/19/19). "Press Release: HalioDx Signs an Exclusive Agreement with Genecast to Make Immunoscore Available in China". Marseille....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top